Abstract
[This corrects the article DOI: 10.1371/journal.pone.0185862.].
Highlights
The authors have provided a corrected version here
All treatments were tolerated with minimal body weight loss, One way ANOVA, Ã p
Student’s t test at the 24 hr time point, Ã p
Read more 
Summary
Introduction
The authors have provided a corrected version here. (a) Combination of cobimetinib and GDC-0994 demonstrates significantly greater anti-tumor activity in multiple KRAS mutant tumor models A549 and NCI-H2122 (cobimetinib at 5 mg/kg, PO, QD + GDC-0994 at 60 mg/kg, PO, QD) compared to single agent (upper panels).
Results
Conclusion
Sign-in/Register to view highlights & summary Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call